Several biopharmas executed high‑value licensing deals over the holidays to shore up oncology pipelines. AbbVie paid upfront and milestone consideration to gain ex‑China rights to Zelgen’s trispecific T‑cell engager alveltamig (ZG‑006), a DLL3‑targeted oncology asset; Gilead licensed Repare’s Polθ inhibitor RP‑3467 in a smaller deal tied to synthetic‑lethality programs. Companies used licensing to buy clinical‑stage assets rather than in‑house discovery, shifting development risk while securing pipeline continuity. These transactions underscore active end‑of‑year partnering to accelerate access to multispecific immunotherapies and DNA‑repair targeted small molecules.